Finished dosage facility of Granules in Hyderabad gets 11 U.S. FDA observations
Conducted from October 19-30, the current good manufacturing practice inspection (CGMP) concluded with the issuance of a Form FDA 483 containing eleven observations. Photo courtesy: granulesindia.com Generic drugmaker Granules India’s finished dosage facility in Gagillapur, Hyderabad, has been issued 11 observations by the U.S. Food and Drug Administration (USFDA) following an inspection. Conducted from October…
Read More “Finished dosage facility of Granules in Hyderabad gets 11 U.S. FDA observations” »